Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (November 2018)
12 slides from Imugene's shareholder meeting presentation, Nov 13, 2018
Slide 1: Harnessing B-Cells for Cancer Immunotherapy
For personal use only HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY Leslie Chong Managing Director & Chief Executive Officer v AGM November. 2018 Developing Cancer Immunotherapies
Slide 2: Executive Summary
EXECUTIVE SUMMARY For personal use only Experienced Imugene B-cell Synergistic Technology Management & Board Vaccine Pipeline Licensed from Ohio State University and The Mayo Meeting milestones Broadened and strengthened clinical Clinic Successful M&A activity programs globally, including U.S. a
Slide 3: A Team with a Track Record in Drug Development
A TEAM WITH A TRACK RECORD IN DRUG DEVELOPMENT For personal use only Leslie Chong (Sydney, Australia) Managing Director & Chief Executive Officer • Over 20 years of oncology experience in Phase I – III of clinical program development Dr Mark Marino (California, U.S.A.) • Leadership role involvement
Slide 4: Imugene Scientific Advisory Board
IMUGENE SCIENTIFIC ADVISORY BOARD For personal use only Prof Pravin Kaumaya Ohio State University, U.S.A. • Prof of Medicine Department of Obstetric Gynecology at Ohio State University Prof. Ursula Wiedermann-Schmidt • Research focus in tumour immunology, mechanisms of tumour cell-immune cell intera
Slide 5: A Better Way to Make Antibodies to Treat Cancer?
A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER? For personal use only In a facility: Using B-cells in your body VS v B-cells are cells in the human body that naturally produce millions of antibodies For example, Merck’s PD-1 inhibitor Keytruda Teaching B-cells to make antibodies using peptide antig
Slide 6: Current Phase 1b/2 in Gastric Cancer
CURRENT PHASE 1B/2, IN GASTRIC CANCER For personal use only Phase 1b Lead-in Phase 2 • Open label • Open label • ~Up to 18 patients in 3 cohorts of up to 6 pts per • ~70 patients from sites in Asia cohort • Combination with chemo • Combination with chemo/cisplatin • Randomized • Endpoints: • Primary
Slide 7: Strategic Acquisition: Worldwide Exclusive License
STRATEGIC AQUISITION For personal use only WORLDWIDE EXCLUSIVE LICENSE v Three year Six patent IND ready PD-1 Ongoing Her-2 Six additional clinical candidates R&D contract with families, clinical trial clinical trial Her-1, Her-2, Her-3, access to Ohio 22 patents (Phase 1) (Phase 2) VEGF, IGF-1R CD2
Slide 8: Prof Pravin Kaumaya & Dr Tanios Bekaii Saab
PROF PRAVIN KAUMAYA & DR TANIOS BEKAII SAAB For personal use only v 7
Slide 9: Imugene Pipeline
IMUGENE PIPELINE For personal use only CLINIC OR CLINIC READY CLINICAL DEVELOPMENT PROGRAM PRE-CLINICAL PHASE 1 PHASE 2 HER-Vaxx (HER2) B-Vaxx (HER2) KEY-Vaxx (PD-1) Her-2 & PD-1 Combo v DISCOVERY PIPELINE PROGRAM DISCOVERY/PRE-CLINICAL ID OF CANDIDATE Her-1 (EGFR) Her-3 IGF-1R VEGF Combination (num
Slide 10: PD-1 KEY-Vaxx Vaccine Phase Development Path 2018-2019
PD-1 “KEY-VAXX” VACCINE PHASE 1 DEVELOPMENT PATH 2018-2019 For personal use only Finalise regulatory PD-1 Formal IND submissions 2019: Commence candidate vaccine CMC Phase 1 manufacturing pre-clinical Identified May, 2018 v Proposed Adaptive Phase 1/2 Expansions Assumption PD-1 Vaccine Design Cohort
Slide 11: Financial Summary
FINANCIAL SUMMARY For personal use only ASX:IMU Options on issue No. of options Exercise Price Expiry Listed: Market Cap (Nov 18): $75.8M AUD, $54.5M USD 242.5M $0.026 30/11/2020 (IMUOA) Listed: 248.3M $0.04 30/11/2021 (IMUOB) Ordinary Shares: 3.610 billion Unlisted: 59.5M $0.0247* 09/03/2020* 12 mo
Slide 12: Leslie Chong contact details
For personal use only Leslie Chong Chief Executive Officer & v Managing Director leslie.chong@imugene.com +61 458 040 433